Melanocortin receptor agonist peptide (FDA-approved for HSDD)
Bremelanotide
An FDA-approved melanocortin peptide for hypoactive sexual desire disorder in premenopausal women; studied for arousal effects.
- Evidence:
- Moderate human evidence
- Status:
- FDA-approved for specific labeled indications
- Reviewed:
- 2026-08-03
Also known as: Bremelanotide, Vyleesi
What is Bremelanotide?
An FDA-approved melanocortin peptide for hypoactive sexual desire disorder in premenopausal women; studied for arousal effects.
This profile is educational. It organizes publicly discussed research context for Bremelanotide and related naming aliases — it is not a treatment guide.
Proposed mechanism
MC3R/MC4R agonism in central nervous system modulates sexual desire and arousal pathways independent of vascular mechanisms.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Moderate human evidence
Preclinical evidence grade: Moderate human evidence
Bremelanotide (Vyleesi) is FDA approved for acquired HSDD in premenopausal women. RECLAIM trials demonstrated improved desire and distress measures. Unlike PDE5 inhibitors, acts centrally. Human evidence is moderate within approved population. Off-label discussion for other populations lacks equivalent evidence.
Key uncertainties
- Efficacy in men or other populations
- Long-term hyperpigmentation management
Research areas being studied
- Sexual desire disorder
- Melanocortin neuroscience
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Nausea
- Flushing
- Headache
- Injection-site reactions
- Hyperpigmentation
Additional risks & considerations
- Nausea (common)
- Hyperpigmentation with repeated use
- Blood pressure increases transiently
- Not for use with cardiovascular contraindications per label
Regulatory status
FDA-approved for specific labeled indications
FDA approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Bremelanotide?
An FDA-approved melanocortin peptide for hypoactive sexual desire disorder in premenopausal women; studied for arousal effects.
How does Bremelanotide work (proposed mechanism)?
MC3R/MC4R agonism in central nervous system modulates sexual desire and arousal pathways independent of vascular mechanisms.
What is Bremelanotide being researched for?
Bremelanotide has been discussed in research contexts including: Sexual desire disorder, Melanocortin neuroscience.
What does current evidence say about Bremelanotide?
Moderate human evidence. Bremelanotide (Vyleesi) is FDA approved for acquired HSDD in premenopausal women. RECLAIM trials demonstrated improved desire and distress measures. Unlike PDE5 inhibitors, acts centrally. Human evidence is moderate within approved population. Off-label discussion for other populations lacks equivalent evidence.
What safety considerations are noted for Bremelanotide?
Reported or discussed considerations include: Nausea; Flushing; Headache; Injection-site reactions; Hyperpigmentation; Nausea (common); Hyperpigmentation with repeated use; Blood pressure increases transiently. This is educational information, not medical advice.
Is Bremelanotide FDA approved?
FDA-approved for specific labeled indications. FDA approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.
References & sources
- Simon JA et al. (2019). Bremelanotide for hypoactive sexual desire disorder (RECLAIM trials) — Obstet Gynecol. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for Bremelanotide or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.